GlycoEra Raises $130M to Advance Protein Degraders Toward Clinic

GlycoEra, backed by major pharma investors including Novo Holdings, has raised $130 million in a Series B round to accelerate its pipeline of protein degraders for autoimmune diseases.124

The company’s lead program, GE8820, is a bispecific degrader that selectively targets and depletes pathogenic IgG4 autoantibodies, which are implicated in diseases such as muscle-specific kinase myasthenia gravis, pemphigus, primary membranous nephropathy, and autoimmune encephalitis.124

GE8820 has shown rapid, deep, and sustained IgG4 depletion in preclinical models, offering a unique treatment approach without traditional immunosuppression.124

GlycoEra plans to initiate its first-in-human clinical trials for GE8820 later in 2025.1234

The funding will also support advancement of a second pipeline program and broader development of GlycoEra’s extracellular protein degrader platform, which utilizes a one-step recombinant technology for efficiency and scalability.24

Investors view this round as strong validation of GlycoEra’s proprietary technology, which aims to deliver highly precise, sustained, and off-target-sparing protein degradation therapies for precision immunology.124

Sources:

1. https://www.biospace.com/business/novo-backed-glycoera-raises-130m-to-advance-protein-degraders-for-precision-immunology

2. https://www.globenewswire.com/news-release/2025/05/27/3088461/0/en/GlycoEra-AG-Raises-130-Million-to-Advance-Novel-Pipeline-of-Extracellular-Protein-Degraders-for-the-Treatment-of-Autoimmune-Diseases.html

3. https://endpts.com/investors-pump-130m-into-protein-degrader-startup-glycoera/

4. https://www.glycoera.com/2025/05/glycoera-ag-raises-130-million-to-advance-novel-pipeline-of-extracellular-protein-degraders-for-the-treatment-of-autoimmune-diseases/